Director's Share Purchase

RNS Number : 6144G

Oxford Biomedica PLC

10 June 2013

 

Oxford BioMedica plc

Director's Share Purchase

Oxford, UK - 10 June 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 7 June 2013 that six of its Directors had acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

				Interest after purchase
Director / PDMR	Title	Price per share (p)	Number of Ordinary Shares acquired on 07 June 2013	Number of Ordinary Shares	% of total issued share capital
Paul Blake	NED	1.750	113,097	533,097	0.037%
John Dawson	CEO	1.750	282,829	2,282,829	0.161%
Andrew Heath	NED	1.789	180,000	500,000	0.035%
Peter Nolan	SVP	1.750	169,675	733,313	0.052%
Nick Rodgers	Chairman	1.750	282,829	634,829	0.045%
Timothy Watts	CFO	1.750	282,829	3,282,829	0.232%

The issued share capital of the Company is 1,416,149,005 1p ordinary shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Nomura Code Securities Limited: Juliet Thompson/Jonathan Senior/Christopher Golden	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications	Tel: [phone]

Notes to editors

1. About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

RDSQDLFBXQFLBBE